Person: ALSAN ÇETİN, İLKNUR
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ALSAN ÇETİN
First Name
İLKNUR
Name
25 results
Search Results
Now showing 1 - 10 of 25
Publication Open Access Oncological outcomes for encapsulated papillary carcinoma of the breast: Multicentric study of Turkish Society for Radiation Oncology breast cancer study group (TROD 06-014 study).(2022-12-04) ALSAN ÇETİN, İLKNUR; Gurdal N., Yildirim B. A. , Gursel O. K. , Ozkurt S., Ibis K., Gultekin M., Tepetam H., Gul S. K. , Guzeloz Z., Oksuz D. C. , et al.Publication Metadata only Kanser ile barışmak(Dünya Yayınları, 2023-02-01) ALSAN ÇETİN, İLKNUR; Alsan Çetin İ.Publication Open Access Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment(2022-08-01) AKIN TELLİ, TUĞBA; ÖZGÜVEN, SALİH; FİLİZOĞLU, NUH; ÖZTÜRK, MEHMET SAADEDDİN; ARIKAN, RUKİYE; DEMİRCAN, NAZIM CAN; BAŞOĞLU TÜYLÜ, TUĞBA; ALSAN ÇETİN, İLKNUR; ÖNEŞ, TUNÇ; DANE, FAYSAL; YUMUK, PERRAN FULDEN; AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T., et al.Objective We aimed to evaluate whether baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters could be used as predictive biomarkers for survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line treatment. Materials and methods This retrospective study included 54 mCRPC patients, who underwent baseline Ga-68-PSMA PET/CT imaging within 1 month before starting first-line treatment. Pre-treatment prostate-specific antigen (PSA) levels and treatments were recorded. SUVmax, SUVmean, whole-body PSMA-derived tumor volume (wbPSMA-TV), and whole-body total lesion PSMA (wbTL-PSMA) were calculated for all patients. PSA response was defined as a decline of >= 50% from pre-treatment value at 12 weeks. Overall survival (OS) was measured from the start of the first-line treatment for mCRPC. Results Docetaxel and abiraterone/enzalutamide were administered to 32 and 22 patients in the first-line setting, respectively. wbPSMA-TV (rho = 0.582, p = 0.004) and wbTL-PSMA (rho = 0.564, p = 0.007) showed moderate positive correlations with PSA levels. Older age (p = 0.02), higher wbPSMA-TV (p = 0.007), higher PSA (p = 0.01), higher number of bone metastases (p = 0.02), and lack of PSA response (p = 0.03) were significantly associated with an increased risk of mortality. Multivariate analysis determined wbPSMA-TV (HR: 1.003, 95% CI 1.001-1.004, p = 0.001) and PSA response (HR: 2.241, 95% CI 1.189-4.222, p = 0.01) as independent predictors of OS. Conclusion The wbPSMA-TV may be a useful tool to reflect tumor burden and predict survival outcomes in patients with mCRPC.Publication Metadata only SARS COV-2 pandemisi sırasında tedavi gören kanser hastaları ve yakınlarınınmemnuniyet, yaşam kaliteleri ve anksiyete durumlarının değerlendirilmesi: Kesitsel anket çalışması(2022-05-27) ALSAN ÇETİN, İLKNUR; şükürov t., akarcay M. K., Onaylar Z., anlar E., demir M., devran b. z., ALSAN ÇETİN İ.Publication Metadata only Enkapsüler papiller meme karsinomunda onkolojik sonuçlar: (TROD 06-014 çalışması(2023-12-07) ALSAN ÇETİN, İLKNUR; GÜRDAL N., YILDIRIM B., kandemir gürsel o., özkurt s., İBİŞ K., GÜLTEKİN M., TEPETAM H., KARABULUT GÜL Ş., GÜZELÖZ ÇAPAR Z., ÇOLPAN ÖKSÜZ D., et al.Publication Metadata only Vulva tutulumu olan alveoler rabdomyosarkomu olgu sunumu(2023-12-07) ALSAN ÇETİN, İLKNUR; kornienko a., çeşmecioğlu e., ALSAN ÇETİN İ.Publication Open Access Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients(2022-11-01) ALSAN ÇETİN, İLKNUR; Alsan Çetin İ., Akay S. U. , Şengöz K. M.Background In this study, we investigated the ability of prostate-specific antigen (PSA) 12 months after (nPSA12) external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) to predict biochemical recurrence-free survival (BRFS), overall survival (OS), and prostate cancer-specific mortality (PCSM) in intermediateand high-risk prostate cancer patients. Methods We retrospectively reviewed the clinical data of 338 intermediate- and high-risk prostate cancer patients treated with EBRT with ADT at our institution between 2000 and 2018. The median radiation dose was 76 Gy, the median initial PSA level was 17 ng/mL (range, 1–228 ng/mL), and the median duration of ADT was 24 months (range, 6–167 months). The median PSA level 1 months after EBRT was 0.06 ng/mL (range, 0–25.6 ng/mL). Univariate and multivariate analyses were performed. Patient survival was assessed using the Kaplan-Meier method and Cox proportional hazards regression analyses. Results The median follow-up time was 5 years (range, 1–20 years). Multivariate analysis revealed that nPSA was an independent and significant factor associated with OS, PCSM, and BRFS (P = 0.008, P = 0.001, P = 0.04). Furthermore, the time to nPSA12 was an independent predictor of PCSM and BRFS (P = 0.042, P = 0.021). Pelvic irradiation was also significantly associated with worse OS and PCSM (P = 0.004, P = 0.01). Additionally, age (≤ 70 or > 70 years) and hormone therapy duration (6 months, 1–3 years, or > 3 years) were significantly associated with OS and PCSM, respectively (P = 0.004, P = 0.02). For high risk, nPSA and nPSA12 were an independent predictor for BRFS. (P = 0.021, P = 0.029) Conclusion The nPSA12 level of > 0.06 ng/mL may independently predict worse PCSM and BRFS in intermediateand high-risk prostate cancer patients undergoing EBRT and ADT. Additionally, for high risk, nPSA > 0.06 ng/mL and nPSA12 > 0.06 ng/mL may independently predict worse BRFS.Publication Metadata only Testis bifazik Mezotelyoma olgu sunum(2023-12-07) ALSAN ÇETİN, İLKNUR; gündüz H., Eren ö. c., kars m., SARI M., ALSAN ÇETİN İ.Publication Metadata only Serviks kanserli geriatric hastalarda definitive kemoradyoterapi sonuçları: TROD 013-002 geriatrik onkoloji grubu(2023-12-07) ALSAN ÇETİN, İLKNUR; ALSAN ÇETİN İ., Halis h., GÜLTEKİN M., ALANYALI S., ERGEN Ş. A., İBİŞ K., SARPER E. B., GÜZELÖZ ÇAPAR Z., AYDIN B., önder h., et al.Publication Metadata only Prostat kanseri tanılı klinik lenf nod pozitif olan hastaların sonuçları(2023-12-07) ALSAN ÇETİN, İLKNUR; gündüz h. k., ALSAN ÇETİN İ.
- «
- 1 (current)
- 2
- 3
- »